Clinical trial
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem…
NCT00217438 · Fred Hutchinson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00217438 |
|---|---|
| Title | Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma |
| Official title | A Multi-Center Phase III Study of Autologous Transplantation for Patients With Multiple Myeloma Comparing Melphalan 280 mg/m2 + Amifostine With Melphalan 200 mg/m2 + Amifostine |
| Lead sponsor | Fred Hutchinson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma |
| Intervention type | Drug, Genetic, Procedure |
| Interventions | melphalan, amifostine trihydrate, peripheral blood stem cell transplantation, fluorescence in situ hybridization, bone marrow ablation with stem cell support |
| Enrollment | 130 |
| Start date | Jul 1, 2005 |
| Primary completion | Oct 1, 2012 |
| First posted | Sep 22, 2005 |
| Last update posted | Aug 21, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: